Department of Cell Biology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Krakow, Poland.
Front Immunol. 2023 Jan 24;14:1120175. doi: 10.3389/fimmu.2023.1120175. eCollection 2023.
In the last few decades, the practical use of stem cells (SCs) in the clinic has attracted significant attention in the regenerative medicine due to the ability of these cells to proliferate and differentiate into other cell types. However, recent findings have demonstrated that the therapeutic capacity of SCs may also be mediated by their ability to secrete biologically active factors, including extracellular vesicles (EVs). Such submicron circular membrane-enveloped vesicles may be released from the cell surface and harbour bioactive cargo in the form of proteins, lipids, mRNA, miRNA, and other regulatory factors. Notably, growing evidence has indicated that EVs may transfer their bioactive content into recipient cells and greatly modulate their functional fate. Thus, they have been recently envisioned as a new class of paracrine factors in cell-to-cell communication. Importantly, EVs may modulate the activity of immune system, playing an important role in the regulation of inflammation, exhibiting broad spectrum of the immunomodulatory activity that promotes the transition from pro-inflammatory to pro-regenerative environment in the site of tissue injury. Consequently, growing interest is placed on attempts to utilize EVs in clinical applications of inflammatory-related dysfunctions as potential next-generation therapeutic factors, alternative to cell-based approaches. In this review we will discuss the current knowledge on the biological properties of SC-derived EVs, with special focus on their role in the regulation of inflammatory response. We will also address recent findings on the immunomodulatory and pro-regenerative activity of EVs in several disease models, including and preclinical, as well as clinical studies. Finally, we will highlight the current perspectives and future challenges of emerging EV-based therapeutic strategies of inflammation-related diseases treatment.
在过去的几十年中,由于这些细胞能够增殖并分化为其他细胞类型,因此干细胞 (SCs) 在临床上的实际应用在再生医学中引起了极大关注。然而,最近的发现表明,SCs 的治疗能力也可能与其分泌具有生物活性的因子的能力有关,包括细胞外囊泡 (EVs)。这些亚微米圆形膜包被的囊泡可能从细胞表面释放出来,并以蛋白质、脂质、mRNA、miRNA 和其他调节因子的形式携带生物活性货物。值得注意的是,越来越多的证据表明,EVs 可以将其生物活性物质转移到受体细胞中,并极大地调节其功能命运。因此,它们最近被视为细胞间通讯中一类新的旁分泌因子。重要的是,EVs 可以调节免疫系统的活性,在炎症的调节中发挥重要作用,表现出广泛的免疫调节活性,促进组织损伤部位从促炎向促再生环境的转变。因此,人们越来越关注尝试将 EVs 用于与炎症相关的功能障碍的临床应用,作为细胞治疗方法的替代方法,作为潜在的下一代治疗因子。在这篇综述中,我们将讨论关于 SC 衍生 EVs 的生物学特性的现有知识,特别关注它们在调节炎症反应中的作用。我们还将讨论 EVs 在几种疾病模型中的免疫调节和促再生活性的最新发现,包括临床前和临床研究。最后,我们将强调新兴基于 EV 的治疗策略在炎症相关疾病治疗中的当前观点和未来挑战。